The Use of Dalbavancin with a Dermal Substitute Application - a
Case Report

J 2021

The Use of Dalbavancin with a Dermal Substitute Application - a Case Report

LIPOVÝ, Břetislav, Martin HLADÍK, Petra BOŘILOVÁ LINHARTOVÁ a Markéta HANSLIANOVÁ

Základní údaje

Originální název

The Use of Dalbavancin with a Dermal Substitute Application - a Case Report

Autoři

LIPOVÝ, Břetislav (203 Česká republika, garant), Martin HLADÍK (703 Slovensko), Petra BOŘILOVÁ LINHARTOVÁ (203 Česká republika, domácí) a Markéta HANSLIANOVÁ (203 Česká republika)

Vydání

Acta chirurgiae plasticae, Praha, Mladá fronta a.s. 2021, 0001-5423

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30212 Surgery

Stát vydavatele

Česká republika

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Kód RIV

RIV/00216224:14110/21:00120141

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.48095/ccachp202114

Klíčová slova anglicky

Dalbavancin; Dermal Substitute Application

Štítky

rivok

Příznaky

Recenzováno

Změněno: 29. 4. 2022 08:41, Mgr. Tereza Miškechová

Anotace

V originále

The application of dermal substitutes is currently becoming increasingly important in the local therapy of a wide range of acute and chronic full-thickness wounds [1]. Dermal substitutes provide two basic functions of the cutaneous dermal layer: control of pain and scarring. They act as matrices or scaffolds, promote new tissue growth and enhance wound healing. The control of the whole process of scarring after the application of dermal substitutes also leads to a reduction in the risk of pathological scars – hypertrophic or keloid scars [2]. One of the biggest challenges associated with the application of dermal substitutes in general is the risk of developing infectious complications – skin and soft tissue infections (SSTIs). A specific subunit of SSTIs, acute bacterial skin and soft tissue infections (ABSSTIs), is defined as a SSTI with a proven bacterial causative agent together with a minimum affected area of 75 cm2 [3]. In this case report, we present a complicated case of multiple SSTIs in a young woman at high risk of developing phlebitis and significant intolerance to a variety of antimicrobials, in which we managed to control the dramatic picture with dalbavancin.

Návaznosti

NU20-05-00166, projekt VaV

Název: Nové přístupy k hojení infikovaných ran pomocí hydrogelů z přírodní pryskyřice Gum Karaya modifikovaných inovativními komponenty cílenými na multirezistentní kmeny bakterií (Akronym: NPHIRPHGK)

Investor: Ministerstvo zdravotnictví ČR, Nové přístupy k hojení infikovaných ran pomocí hydrogelů z přírodní pryskyřice Gum Karaya modifikovaných inovativními komponenty cílenými na multirezistentní kmeny bakterií, Podprogram 1 - standardní

Citovat

LIPOVÝ, Břetislav, Martin HLADÍK, Petra BOŘILOVÁ LINHARTOVÁ a Markéta HANSLIANOVÁ. The Use of Dalbavancin with a Dermal Substitute Application - a Case Report. Acta chirurgiae plasticae. Praha: Mladá fronta a.s., 2021, roč. 63, č. 1, s. 14-17. ISSN 0001-5423. Dostupné z: https://dx.doi.org/10.48095/ccachp202114.

@article{1791017,
   author = {Lipový, Břetislav and Hladík, Martin and Bořilová Linhartová, Petra and Hanslianová, Markéta},
   article_location = {Praha},
   article_number = {1},
   doi = {http://dx.doi.org/10.48095/ccachp202114},
   keywords = {Dalbavancin; Dermal Substitute Application},
   language = {eng},
   issn = {0001-5423},
   journal = {Acta chirurgiae plasticae},
   title = {The Use of Dalbavancin with a Dermal Substitute Application - a Case Report},
   url = {https://www.prolekare.cz/en/journals/acta-chirurgiae-plasticae/2021-1-24/the-use-of-dalbavancin-with-a-dermal-substitute-application-a-case-report-126934},
   volume = {63},
   year = {2021}
}

TY  - JOUR
ID  - 1791017
AU  - Lipový, Břetislav - Hladík, Martin - Bořilová Linhartová, Petra - Hanslianová, Markéta
PY  - 2021
TI  - The Use of Dalbavancin with a Dermal Substitute Application - a Case Report
JF  - Acta chirurgiae plasticae
VL  - 63
IS  - 1
SP  - 14-17
EP  - 14-17
PB  - Mladá fronta a.s.
SN  - 00015423
KW  - Dalbavancin
KW  - Dermal Substitute Application
UR  - https://www.prolekare.cz/en/journals/acta-chirurgiae-plasticae/2021-1-24/the-use-of-dalbavancin-with-a-dermal-substitute-application-a-case-report-126934
N2  - The application of dermal substitutes is currently becoming increasingly important in the local therapy of a wide range of acute and chronic full-thickness wounds [1]. Dermal substitutes provide two basic functions of the cutaneous dermal layer: control of pain and scarring. They act as matrices or scaffolds, promote new tissue growth and enhance wound healing. The control of the whole process of scarring after the application of dermal substitutes also leads to a reduction in the risk of pathological scars – hypertrophic or keloid scars [2]. One of the biggest challenges associated with the application of dermal substitutes in general is the risk of developing infectious complications – skin and soft tissue infections (SSTIs). A specific subunit of SSTIs, acute bacterial skin and soft tissue infections (ABSSTIs), is defined as a SSTI with a proven bacterial causative agent together with a minimum affected area of 75 cm2 [3]. In this case report, we present a complicated case of multiple SSTIs in a young woman at high risk of developing phlebitis and significant intolerance to a variety of antimicrobials, in which we managed to control the dramatic picture with dalbavancin.
ER  -

LIPOVÝ, Břetislav, Martin HLADÍK, Petra BOŘILOVÁ LINHARTOVÁ a Markéta HANSLIANOVÁ. The Use of Dalbavancin with a Dermal Substitute Application - a Case Report. \textit{Acta chirurgiae plasticae}. Praha: Mladá fronta a.s., 2021, roč.~63, č.~1, s.~14-17. ISSN~0001-5423. Dostupné z: https://dx.doi.org/10.48095/ccachp202114.

Podrobný výpis o publikaci